Fluoride Gels Help Prevent and Control Dental Caries | ACFF
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Fluorides for Preventing Early Tooth Decay (Demineralised Lesions) During Fixed Brace Treatment
This is a repository copy of Fluorides for preventing early tooth decay (demineralised lesions) during fixed brace treatment. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/154038/ Version: Published Version Article: Benson, P.E. orcid.org/0000-0003-0865-962X, Parkin, N., Dyer, F. et al. (2 more authors) (2019) Fluorides for preventing early tooth decay (demineralised lesions) during fixed brace treatment. Cochrane Database of Systematic Reviews, 2019 (11). CD003809. ISSN 1469-493X https://doi.org/10.1002/14651858.cd003809.pub4 This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2019, Issue 11. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.’ + ' Benson PE, Parkin N, Dyer F, Millett DT, Germain P., Fluorides for preventing early tooth decay (demineralised lesions) during fixed brace treatment. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD003809. DOI: http://dx.doi.org/10.1002/14651858.CD003809.pub4. Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. -
Precautions Interactions Pharmacokinetics
Sodium Silicofluoride 2091 7. McDonagh MS, et al. Systematic review of water fluoridation. BMJ 2000; r r Crest; Sensodyne iso-active; Soluvite; Tri-A-Vite F; Tri-Vi-Flor; 321: 855-9. P.. �P.?. c:Jii?,n,�............................. ............................................. Tri-Vi-Floro; Trivitamin Fluoride Drops; Vi-Daylin/F; Venez. : 8. Rock WP, Sabieha AM The relationship between reported toothpaste . (details are given in Volume B) Sensodyne. usage in infancy and fluorosis of permanent incisors. Br Dent J 1997; 183: ProprietaryPreparations 165-70. Single-ingredientPrepara6ons, Arg. : Aquafresh Ultimate White; 9. Steiner M, et al. Effect of 1000 ppm relative to 250 ppm fluoride Elgydium Junior; Elgydium ProtecTion Caries; Fluordent; PharmacopoeialPrepara6ons toothpaste: a meta-analysis. Am J Dent 2004; 17: 85-8. BP 2014: Sodium Fluoride Mouthwash; Sodium Fluoride Oral Fluorogel; Fluoroplat; Naf Buches; Opalescence; Austral.: Flur Drops; Sodium Fluoride Oral Solution; Sodium Fluoride Tablets; etst; NeutraFluor; Austria: Duraphat; Fluodontt; Sensodyne 36: Gum disease. In the Davangere district of India, the fluo USP Minerals Capsules; Minerals Tablets; Oil- and Water Proschmelz; Zymafluor; Belg.: Fluodontyl; Fluor; Z-Fluor; soluble Vitamins with Minerals Capsules; Oil- and Water-soluble ride concentration in the drinking water ranges from 1.5 Braz.: Fluotrat; Canad. : Fluocalt; Fluor-A-Day; Nafrinset; Oro Vitamins with Minerals Oral Solution; Oil- and Water-soluble to 3 ppm; there is virtually no dental care. In a study of NaFt; -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Pharmaceutical Appendix to the Harmonized Tariff Schedule
Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
Effect of 10% Fluoride on the Remineralization of Dentin in Situ
www.scielo.br/jaos http://dx.doi.org/10.1590/1678-775720150239 dentin in situ 0R]KJDQ %,=+$1*1, Sabine KALETA-KRAGT1, Preeti SINGH-HÜSGEN2, Markus Jörg ALTENBURGER3, Stefan ZIMMER1 1- University Witten/Herdecke, Department of Operative and Preventive Dentistry, Witten, Germany. 2- Heinrich-Hein University Duesseldorf, Department of Operative and Preventive Dentistry and Periodontics, Duesseldorf, Germany. 3- Universitätsklinikum Freiburg, Department of Operative Dentistry and Periodontology, Freiburg, Germany. Corresponding address: Mozhgan Bizhang - University Witten/Herdecke - Department of Operative and Preventive Dentistry - Alfred-Herrhausen-Str. 50 - 58448 Witten - Germany - Phone: +49 2302 926 653 - Fax +49 2302 926 661 - e-mail: [email protected] 6XEPLWWHG0D\0RGL¿FDWLRQ$XJXVW$FFHSWHG6HSWHPEHU ABSTRACT bjective: The purpose of this randomized, cross-over, in situ study was to determine Othe remineralization of demineralized dentin specimens after the application of a 10% uoride - or a 1% chlorheidine1% thymol thymol varnish aterial and ethods: Twelve individuals without current caries activity wore removable appliances in the lower jaw for a period of four weeks. Each appliance contained four human demineralized dentin specimens ed on the buccal aspects. The dentin specimens were obtained from the cervical regions of extracted human third molars. After demineralization, half the surface of each specimen was covered with a nail varnish to serve as the reference surface. The dentin specimens were randomly assigned to one of the three groups: F-, CHX–thymol, and control no treatment. efore the rst treatment period and between the others, there were washout periods of one week. After each treatment phase, the changes in mineral content (vol% μm) and the lesion depths (μm) of the dentin slabs were determined by transverse microradiography (TMR). -
An in Vitro and in Vivo Study of Fluoride Uptake by Dentine Following Application of Various Topical Fluoride Regimens
AN IN VITRO AND IN VIVO STUDY OF FLUORIDE UPTAKE BY DENTINE FOLLOWING APPLICATION OF VARIOUS TOPICAL FLUORIDE REGIMENS Nicola Jane Woodley A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Dentistry University of London Departments of Biomaterials and Prosthetic Dentistry Eastman Dental Institute for Oral Health Care Sciences -1999- ProQuest Number: U641832 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U641832 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Restoration of severely worn dentitions frequently involves the use of overlay dentures. Such treatment can lead to the rapid development of caries. Topical fluoride regimens, including sodium fluoride, amine fluoride or stannous fluoride, have been used to reduce this risk. Sodium fluoride is regarded as effective but the other two compounds to be evaluated have benefits such as deposition of acid insoluble salts on the tooth surface. However stannous fluoride can be unstable and it has been suggested that amine fluoride/stannous fluoride combinations may be more effective. This study investigated the three fluoride containing compounds both alone and in combination to measure the effects on the fluoride content of dentine both in vitro and in vivo. -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
Oral Care Compositions Containing Free-B-Ring Flavonoids and Flavans
(19) & (11) EP 2 308 565 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.04.2011 Bulletin 2011/15 A61Q 11/02 (2006.01) A61Q 11/00 (2006.01) A61K 8/19 (2006.01) A61K 8/21 (2006.01) (2006.01) (2006.01) (21) Application number: 11151708.2 A61K 8/25 A61K 8/27 A61K 8/29 (2006.01) A61K 8/49 (2006.01) (2006.01) (2006.01) (22) Date of filing: 21.12.2005 A61K 8/81 A61P 29/00 (84) Designated Contracting States: • Viscio, David AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Monmouth Junction, NJ 08852 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Gaffar, Abdul SK TR Princeton, NJ 08540 (US) • Mello, Sarita V. (30) Priority: 22.12.2004 US 639331 P Somerset, NJ 08873 (US) 12.12.2005 US 301098 • Arvanitidou, Evangelia S. Princeton, NJ 08540 (US) (62) Document number(s) of the earlier application(s) in • Prencipe, Michael accordance with Art. 76 EPC: West Windsor, NJ 08550 (US) 05855133.4 / 1 827 608 (74) Representative: Jenkins, Peter David (71) Applicant: Colgate-Palmolive Company Page White & Farrer New York NY 10022-7499 (US) Bedford House John Street (72) Inventors: London WC1N 2BF (GB) • Xu, Guofeng Princeton, NJ 08542 (US) Remarks: • Boyd, Thomas, J. This application was filed on 21-01-2011 as a Metuchen, NJ 08840 (US) divisional application to the application mentioned • Hao, Zhigang under INID code 62. North Brunswick, NJ 08902 (US) (54) ORAL CARE COMPOSITIONS CONTAINING FREE-B-RING FLAVONOIDS AND FLAVANS (57) Oral care compositions containing: a free-B-ring flavonoid and a flavan; as well as at least one bioavailability- enhancing agent are provided. -
(12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al. -
(12) United States Patent (10) Patent No.: US 9,693,956 B2 Seigfried (45) Date of Patent: *Jul
USOO9693956B2 (12) United States Patent (10) Patent No.: US 9,693,956 B2 Seigfried (45) Date of Patent: *Jul. 4, 2017 (54) LIQUID COMPOSITIONS CAPABLE OF 5,556,638 A 9, 1996 Wunderlich et al. FOAMING AND INCLUDING ACTIVE 5,560,924 A 10, 1996 Wunderlich et al. 5,565,613 A 10/1996 Geisslinger et al. AGENTS, AND METHODS FOR MAKING OR 5,580,491 A 12/1996 Phillips et al. DEVELOPNG SAME 5,738,869 A 4/1998 Fischer et al. 5,747,058 A 5/1998 Tipton et al. (71) Applicant: MIKA Pharma GmbH 5,958,379 A 9/1999 Regenold et al. 5,976,566 A 11/1999 Samour et al. (72) Inventor: Bernd G. Seigfried, Limburgerhof 6,066,332 A 5, 2000 Wunderlich et al. 6,165,500 A 12/2000 Cevc (DE) 6,287,592 B1 9, 2001 Dickinson 6,309.663 B1 10/2001 Patel et al. (73) Assignee: MIKA Pharma GmbH 6.432,439 B1 8, 2002 Suzuki et al. 6,464,987 B1 10/2002 Fanara et al. (*) Notice: Subject to any disclaimer, the term of this 6,605,298 B1 8/2003 Leigh et al. 6,645,520 B2 11/2003 Hsu et al. patent is extended or adjusted under 35 6,835,392 B2 12/2004 Hsu et al. U.S.C. 154(b) by 0 days. 7,244447 B2 7/2007 Hsu et al. 7,473.432 B2 1/2009 Cevc et al. This patent is Subject to a terminal dis 9,005,626 B2 4/2015 Seigfried claimer. -
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE -
Drug Consumption at Wholesale Prices in 2017 - 2020
Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8